Guidance And Future OutlookManagement raised the lower end of revenue and EPS guidance, indicating confidence in ongoing growth.
Product Launches And ApprovalsThe company has received FDA approval for the Affera PFA platform and CMS TPT payment approval for the Symplicity renal denervation system, with further FDA submission for Hugo planned.
Revenue Growth And Market PerformanceMedtronic delivered better-than-expected FY2Q25 results, with revenue exceeding consensus, marking the eighth quarter of mid-single-digit revenue growth.